While pralatrexate (PDX) has been successfully developed for the treatment of T‐cell
lymphoma, the mechanistic basis for its T‐cell selectivity and acquired resistance remains …

Background Pralatrexate (PDX) is a novel antifolate approved for the treatment of patients
with relapsed/refractory peripheral T-cell lymphoma, but some patients exhibit intrinsic …

Folates are well known to be essential for many cellular processes, including cellular
proliferation. As a consequence, antifolates, the fraudulent mimics of folic acid, have been …

Pralatrexate is an antifolate designed to be internalized more rapidly than other traditional
antifolates. Preclinical studies have demonstrated its superiority to methotrexate, and early …

Background: Pralatrexate (PDX) is a novel targeted antifolate that is designed to accumulate
preferentially in cancer cells. Pralatrexate selectively enters cells expressing RFC-1, a …

Abstract Abstract 1678 Poster Board I-704 Background The outcome of patients with PTCL is
poor and the majority of patients ultimately have refractory disease to a variety of agents …

PRX belongs to a new class of anti-folates designed to have improved affinity for the
reduced folate carrier. A phase 2 study at 135 mg/m2 given on an every other week (w) …

Abstract Abstract 4881 Background: In a wide range of malignancies, including nonHodgkin
lymphoma (NHL), treatment-naive patients generally show a greater response to …

C85 Pralatrexate is a novel folate analogue designed to have high affinity for the reduced
folate carrier (RFC-1), exhibiting improved internalization and efficacy over other …

Abstract Abstract 919 Background: Pralatrexate enters cancer cells via the reduced folate
carrier-1 (RFC-1) and is efficiently polyglutamated by folylpolyglutamyl synthetase (FPGS) …